Patents Assigned to Xenon Pharmaceuticals
  • BIARYL ETHER SULFONAMIDES AND THEIR USE AS THERAPEUTIC AGENTS
    Publication number: 20140256736
    Abstract: This invention is directed to biaryl ether sulfonamides, or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.
    Type: Application
    Filed: October 30, 2012
    Publication date: September 11, 2014
    Applicant: XENON PHARMACEUTICALS INC.
    Inventors: Shifeng Liu, Thilo Focken, Navjot Chahal, Zaihui Zhang, Renata Marcella Oballa, Julia Fonarev
  • Synthetic methods for spiro-oxindole compounds
    Patent number: 8742109
    Abstract: This invention is directed to methods of preparing certain spiro-oxindole derivatives, which are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: June 3, 2014
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Jean-Jacques Cadieux, Mikhail Chafeev, Sultan Chowdhury, Jianmin Fu, Qi Jia, Stefanie Abel, Emad El-Sayed, Elke Huthmann, Thomas Isarno
  • Methods and reagents for modulating cholesterol levels
    Patent number: 8715968
    Abstract: The invention features ABC1 nucleic acids and polypeptides for the diagnosis and treatment of abnormal cholesterol regulation. The invention also features methods for identifying compounds for modulating cholesterol levels in an animal (e.g., a human).
    Type: Grant
    Filed: December 23, 2003
    Date of Patent: May 6, 2014
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Michael R. Hayden, Angela R. Brooks-Wiison, Simon N. Pimstone
  • N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF
    Publication number: 20130317001
    Abstract: The invention provides novel compounds having the general formula: and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, B, R1, R2, R3, R4, R5 and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: May 21, 2013
    Publication date: November 28, 2013
    Applicants: XENON PHARMACEUTICALS INC., GENENTECH, INC.
    Inventors: Jean-Christophe Andrez, Sultan Chowdhury, Shannon Marie Decker, Christoph Martin Dehnhardt, Thilo Focken, Michael Edward Grimwood, Ivan William Hemeon, Qi Jia, Jun Li, Daniel F. Ortwine, Brian Safina, Tao Sheng, Shaoyi Sun, Daniel P. Sutherlin, Michael Scott Wilson, Alla Yurevna Zenova
  • N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF
    Publication number: 20130317000
    Abstract: The invention provides novel compounds having the general formula: and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, B, R1, R2, R3, R4, R5 and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: May 21, 2013
    Publication date: November 28, 2013
    Applicants: XENON PHARMACEUTICALS INC., GENENTECH, INC
    Inventors: Sultan Chowdhury, Christoph Martin Dehnhardt, Thilo Focken, Michael Edward Grimwood, Ivan William Hemeon, Qi Jia, Daniel Ortwine, Brian Safina, Shaoyi Sun, Daniel P. Sutherlin, Alla Yurevna Zenova
  • Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors
    Patent number: 8541457
    Abstract: Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I), where V, W, R1, R2, R3 and R4 are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.
    Type: Grant
    Filed: June 5, 2006
    Date of Patent: September 24, 2013
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Jianmin Fu, Duanjie Hou, Rajender Kamboj, Vishnumurthy Kodumuru, Natalia Pokrovskaia, Vandna Raina, Shaoyi Sun, Serguei Sviridov, Zaihui Zhang
  • Methods for Identifying Analgesic Agents
    Publication number: 20130210884
    Abstract: The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of using compounds small organic compounds to treat pain as well as to predict the effect of analgesic agents in patients, such as those possessing gain of function mutations.
    Type: Application
    Filed: April 11, 2013
    Publication date: August 15, 2013
    Applicant: Xenon Pharmaceutical Inc.
    Inventors: Marcia MacDonald, Mark Samuels, Robin Sherrington, Yigal Paul Goldberg
  • Juvenile hemochromatosis gene (HFE2A) cleavage products and uses thereof
    Patent number: 8507435
    Abstract: Isolated fragments of the HFE2A protein able to bind and modulate HFE2A and other proteins, such as hepcidin, involved in the iron metabolism pathway are disclosed. Also disclosed are corresponding isolated polynucleotides encoding the fragments of the HFE2A protein. Methods for identifying modulators of HFE2A, comprising contacting a test compound with HFE2A and determining a change in HFE2A activity due to the compound, are provided. Also taught are methods of diagnosing an animal afflicted with or at risk of developing a disease of iron metabolism. Methods for treating and/or preventing a disorder in animals comprising administering to an animal afflicted therewith, or at risk of developing said disorder, a therapeutically effective amount of an HFE2A modulator are provided.
    Type: Grant
    Filed: July 19, 2012
    Date of Patent: August 13, 2013
    Assignee: Xenon Pharmaceuticals, Inc.
    Inventors: Yigal Goldberg, Rajender K. Kamboj
  • Organic compounds
    Patent number: 8501746
    Abstract: The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.
    Type: Grant
    Filed: June 4, 2007
    Date of Patent: August 6, 2013
    Assignees: Xenon Pharmaceuticals Inc., Novartis AG
    Inventors: Natalie Dales, Julia Fonarev, Jianmin Fu, Duanjie Hou, Rajender Kamboj, Vishnumurthy Kodumuru, Natalia Pokrovskaia, Vandna Raina, Shaoyi Sun, Zaihui Zhang
  • Use of spiro-oxindole compounds as therapeutic agents
    Patent number: 8466188
    Abstract: This invention is directed to methods of using spiro-oxindole compounds of formula (I): wherein k, j, Q, R1, R2a, R2b, R2c, R2d, R3a, R3b, R3c, and R3d are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment and/or prevention of hypercholesterolemia, benign prostatic hyperplasia, pruritis and cancer.
    Type: Grant
    Filed: October 12, 2007
    Date of Patent: June 18, 2013
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Mikhail Chafeev, Sultan Chowdhury, Robert Fraser, Jianmin Fu, Rajender Kamboj, Duanjie Hou, Shifeng Liu, Mehran Seid Bagherzadeh, Serguei Sviridov, Shaoyi Sun, Jianyu Sun, Nagasree Chakka, Tom Hsieh, Vandna Raina
  • Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
    Patent number: 8450358
    Abstract: This invention is directed to the (S)-enantiomer of the compound of formula (I): or a pharmaceutically acceptable solvate or prodrug thereof. This (S)-enantiomer is useful for the treatment of diseases or conditions, such as pain, which are ameliorated or alleviated by the modulation of voltage-gated sodium channels.
    Type: Grant
    Filed: June 28, 2010
    Date of Patent: May 28, 2013
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Mikhail Chafeev, Jianmin Fu, Jean-Jacques Cadieux
  • Synthetic methods for spiro-oxindole compounds
    Patent number: 8445696
    Abstract: This invention is directed to methods of preparing certain spiro-oxindole derivatives, which are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.
    Type: Grant
    Filed: October 14, 2010
    Date of Patent: May 21, 2013
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Jean-Jacques Cadieux, Mikhail Chafeev, Sultan Chowdhury, Jianmin Fu, Qi Jia, Stefanie Abel, Emad El-Sayed, Elke Huthmann, Thomas Isarno
  • AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS
    Publication number: 20130096056
    Abstract: Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where V, W, R1, R2, R3 and R4 are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.
    Type: Application
    Filed: September 14, 2012
    Publication date: April 18, 2013
    Applicant: XENON PHARMACEUTICALS INC.
    Inventors: Jianmin Fu, Duanjie Hou, Rajender Kamboj, Vishnumurthy Kodumuru, Natalia Pokrovskaia, Vandna Raina, Shaoyi Sun, Serguei Sviridov, Zaihui Zhang
  • Spiro-oxindole compounds and their uses as therapeutic agents
    Patent number: 8415370
    Abstract: This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.
    Type: Grant
    Filed: July 25, 2012
    Date of Patent: April 9, 2013
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Mikhail Chafeev, Sultan Chowdhury, Lauren Fraser, Jianmin Fu, Jonathan Langille, Shifeng Liu, Jianyu Sun, Shaoyi Sun, Serguei Sviridov, Mark Wood, Alla Yurevna Zenova, Qi Jia, Jean-Jacques Cadieux, Simon J. Gauthier, Amy Frances Douglas, Tom Hsieh, Nagasree Chakka, Zoran Cikojevic
  • Methods for treating pain by inhibition of the SCN9A channel
    Patent number: 8410054
    Abstract: The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of utilizing the SCN9A gene and expression products thereof for the screening and identification of therapeutic agents, including small organic compounds, which are selective for SCN9A, and are useful in the treatment of pain and other disorders. The invention also relates to methods of using these compounds to treat or otherwise ameliorate such disorders.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: April 2, 2013
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Marcia L. MacDonald, Mark E. Samuels, Robin Sherrington, Yigal P. Goldberg
  • PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS
    Publication number: 20130079354
    Abstract: Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): wherein W, V, x, y, R1, R2, R3, R4, R5, R6, R7, R7a, R8, R8a, R9, R9a, R10 and R10a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.
    Type: Application
    Filed: September 14, 2012
    Publication date: March 28, 2013
    Applicant: Xenon Pharmaceuticals Inc.
    Inventors: Melwyn ABREO, Daniel F. HARVEY, Mikhail A. KONDRATENKO, Wenbao LI, Rajender KAMBOJ, Vishnumurthy KODUMURU, Michael D. WINTHER, Heinz W. GSCHWEND, Nagasree CHAKKA, Shifeng LIU, Serguei SVIRIDOV, Shaoyi SUN
  • SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS
    Publication number: 20130072686
    Abstract: This invention is directed to methods of preparing certain spiro-oxindole derivatives, which are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.
    Type: Application
    Filed: September 14, 2012
    Publication date: March 21, 2013
    Applicant: XENON PHARMACEUTICALS INC.
    Inventors: Jean-Jacques Cadieux, Mikhail Chafeev, Sultan Chowdhury, Jianmin Fu, Qi Jia, Stefanie Abel, Emad El-Sayed, Elke Huthmann, Thomas Isarno
  • ENANTIOMERS OF SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS
    Publication number: 20130072537
    Abstract: This invention is directed to the (S)-enantiomer of the compound of formula (I): or a pharmaceutically acceptable solvate or prodrug thereof. This (S)-enantiomer is useful for the treatment of diseases or conditions, such as pain, which are ameliorated or alleviated by the modulation of voltage-gated sodium channels.
    Type: Application
    Filed: September 14, 2012
    Publication date: March 21, 2013
    Applicant: XENON PHARMACEUTICALS INC.
    Inventors: Mikhail Chafeev, Jianmin Fu, Jean-Jacques Cadieux
  • Pyridyl derivatives and their use as therapeutic agents
    Patent number: 8383628
    Abstract: Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): wherein W, V, x, y, R1, R2, R3, R4, R5, R6, R7, R7a, R8, R8a, R9, R9a, R10 and R10a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.
    Type: Grant
    Filed: June 15, 2010
    Date of Patent: February 26, 2013
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Melwyn Abreo, Daniel F. Harvey, Mikhail A. Kondratenko, Wenbao Li, Rajender Kamboj, Vishnumurthy Kodumuru, Michael D. Winther, Heinz W. Gschwend, Nagasree Chakka, Shifeng Liu, Serguei Sviridov, Shaoyi Sun
  • PYRAZOLE DERIVATIVES WHICH MODULATE STEAROYL-COA DESATURASE
    Publication number: 20130011361
    Abstract: The present invention provides heterocyclic derivatives of formula (I) that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.
    Type: Application
    Filed: October 1, 2010
    Publication date: January 10, 2013
    Applicants: XENON PHARMACEUTICALS INC., NOVARTIS AG
    Inventors: Natalie Dales, Jianmin Fu, Qi Jia, Natalia Pokrovskaia, Shaoyi Sun, Zaihui Zhang